Several big transactions have occurred in the spine device market this year.
Here are five big spine device companies making transactions in 2019.
Stryker acquired Mobius Imaging and sister company Cardan Robotics for $500 million. Stryker intends to use the imaging and robotic technologies of Mobius and Cardan to boost its presence in the spine, orthopedic and neurotechnology markets. The acquisition grants Stryker's spine division access to the intraoperative imaging sector and aligns with its navigation and implant portfolio.
Earlier this year, Stryker also acquired OrthoSpace, an Israel-based company focused on technology to treat irreparable rotator cuff tears, for $10 million cash up front and $110 million if the company meets future milestones.
Smith+Nephew acquired Osiris Therapeutics, a bone graft and articular cartilage substitute products company, for $660 million in March. Osiris products include Grafix, a cryopreserved placental membrane skin substitute that treats acute and chronic wounds, as well as BIO4 bone matrix for bone repair. The company's product portfolio also includes Cartiform, an allograft for articular cartilage repair.
The company also acquired Brainlab, boosting its orthopedic joint replacement business. Smith+Nephew will begin integrating the Brainlab platform into the next version of its robotic surgery platform, Navio 7.0.
Johnson & Johnson Medical Shanghai entered into a co-marketing agreement and research and development agreement with the orthopedic robotics market leader in China, Tinavi. The deal allows the company to bring Tinavi's spinal and trauma robotic solution to the China orthopedics implant market. Tinavi's robotic platform includes a robotic arm, intraoperative planning interface and integrated navigation with intraoperative 3D imaging.
DePuy Synthes will acquire the assets of JointPoint in a deal that is set for completion by the end of the year. The company will acquire JointPoint's navigation software, which it plans to develop for further orthopedic procedures. Neither company disclosed financial details of the deal.
RTI Surgical completed the up to $300 million acquisition of Paradigm Spine in March. Paradigm Spine's flagship product, the coflex Interlaminar Stabilization device, is designed to treat moderately severe lumbar spinal stenosis in conjunction with decompression. RTI's existing spine portfolio consists of hardware, interbody and biologic options.